Lung cancer remains one of the world’s greatest unmet needs: in 2022 there were 2.5 million new cases and 1.8 million deaths globally, with a five-year survival rate of just 19%. Many promising therapies fail because they cannot reach their target safely and effectively, leading to poor patient outcomes, side effects and wasted R&D investment. Vector Bioscience has developed a new class of nanoscale drug carriers that deliver treatments directly to diseased tissues, making medicines more effective, reducing side effects and unlocking therapies that were previously undeliverable.
Lluna Gallego Segrelles is the CEO and co-founder of Vector Bioscience, responsible for setting the path ahead and ensuring the company stays aligned with its long-term goals. He describes his role as being, “to identify gaps and fill them, to make sure we are always ready, and to bring out the best of ourselves as we scale.”
Lluna sees the mentoring and coaching as part of the Shott Scale Up Accelerator helping to strengthen his strategic leadership and influence, sharpening his ability to define and communicate a growth strategy while leading high-stakes conversations with investors, partners and internal teams. He also hopes the training will provide practical guidance on financing, cashflow and fundraising mechanics. He says, “My aim is to develop as an authentic leader who can set the path ahead, motivate the team and ensure Vector is always ready to deliver.”
The Shott Scale Up Accelerator comes at a pivotal moment for Vector. Having proven the strength of their technology and built early collaborations, they are now preparing to scale partnering and move towards clinical translation. Going forward Vector will be exploring further opportunities in the US and Europe. They will also be opening a Strategic Catalyst capital raise of £5-7 million within the next 6-12 months. They will use this to expand their executive team with seasoned experts, grow Vector Labs with new equipment and facilities, scale up manufacturing, and complete their preclinical data package.
